|
Time |
Source |
|
Announcement
|
|
01 Aug 2022 |
12:00 pm |
GNW
|
|
|
ObsEva SA |
ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing |
29 Jul 2022 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Announces Management Change |
27 Jul 2022 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Announces Corporate Updates |
|
5:55 am |
GNW
|
|
|
ObsEva SA |
ObsEva Announces Corporate Updates |
28 Jun 2022 |
9:01 pm |
GNW
|
|
|
ObsEva SA |
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids |
17 Jun 2022 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids |
27 May 2022 |
9:01 pm |
GNW
|
|
|
ObsEva SA |
ObsEva Announces Corporate Updates |
25 May 2022 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses |
19 May 2022 |
6:05 am |
GNW
|
|
|
ObsEva SA |
ObsEva Announces Appointment of Annette Clancy as Chair of the Board of Directors |
|
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2022 Annual General Meeting held on May 18, 2022 |
17 May 2022 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate Update |
16 May 2022 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva to Present at the H.C. Wainwright Global Investment 2022 Conference |
12 May 2022 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update |
09 May 2022 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at the 2022 ACOG Annual Clinical and Scientific Meeting |
02 May 2022 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer |
25 Apr 2022 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids |
07 Apr 2022 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Annual General Meeting 2022 |
31 Mar 2022 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Annual Report 2021 |
22 Mar 2022 |
11:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain |
|
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain |
10 Mar 2022 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update |
10 Feb 2022 |
9:11 pm |
GNW
|
|
|
ObsEva SA |
ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix |
04 Feb 2022 |
9:15 pm |
GNW
|
|
|
ObsEva SA |
ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids |
01 Feb 2022 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Appoints Katja Buhrer as Chief Strategy Officer |
28 Jan 2022 |
9:01 pm |
GNW
|
|
|
ObsEva SA |
ObsEva Announces Corporate Updates |
06 Jan 2022 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain |
03 Jan 2022 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva to Present at the H.C. Wainwright BioConnect 2022 Conference |
20 Dec 2021 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Added to the NASDAQ Biotechnology Index |
17 Dec 2021 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids |
13 Dec 2021 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Appoints Will Brown as Chief Financial Officer |
10 Dec 2021 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021 |
02 Dec 2021 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Announces Symposium and Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021 |
22 Nov 2021 |
6:05 am |
GNW
|
|
|
ObsEva SA |
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix |
|
6:00 am |
GNW
|
|
|
ObsEva SA |
Obseva Announces Appointment of Stephanie Brown to its Board of Directors |
04 Nov 2021 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Announces Third Quarter 2021 Financial Results and Business Update |
29 Oct 2021 |
9:30 pm |
GNW
|
|
|
ObsEva SA |
ObsEva Announces Management Change |
20 Oct 2021 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at ASRM 2021 Scientific Congress & Expo |
19 Oct 2021 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Announces Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at ASRM 2021 Scientific Congress & Expo |
13 Oct 2021 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix |
30 Sep 2021 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Announces Appointment of Luigi Marro as Chief Transformation Officer |
15 Sep 2021 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids |
07 Sep 2021 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva to Present at the H.C. Wainwright 23rd Annual Global Investment Conference |
05 Aug 2021 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Announces Second Quarter 2021 Financial Results and Business Update |
04 Aug 2021 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Announces Two Cornerstone Publications Describing Clinical Trials of Nolasiban for Improving Pregnancy and Live Birth Outcomes Following IVF |
03 Aug 2021 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva to Present at Upcoming Investor Conferences |
27 Jul 2021 |
6:00 am |
GNW
|
|
|
ObsEva SA |
Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor |
02 Jul 2021 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting |
30 Jun 2021 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty® (linzagolix) for the Treatment of Severe Adenomyosis at ESHRE Virtual 37th Annual Meeting |
24 Jun 2021 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva To Present Data on Two Clinical Development Programs at ESHRE Virtual 37th Annual Meeting |
10 Jun 2021 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on Ebopiprant (OBE022) for the Treatment of Spontaneous Preterm Labor at the RCOG Virtual World Congress 2021 |
02 Jun 2021 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Announces Oral Presentation at the RCOG Virtual World Congress 2021 |
31 May 2021 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2021 Annual General Meeting held on May 28, 2021 |
25 May 2021 |
9:05 pm |
GNW
|
|
|
ObsEva SA |
ObsEva Announces Proposed Changes to the Composition of its Board of Directors |
20 May 2021 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of Yselty® (linzagolix) for the Treatment of Uterine Fibroids |
06 May 2021 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Announces First Quarter 2021 Financial Results and Business Update |
|
5:55 am |
GNW
|
|
|
ObsEva SA |
ObsEva appoints Clive Bertram as Chief Commercial Officer |
04 May 2021 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Announces Enrollment Completion of Linzagolix Phase 3 EDELWEISS 3 Trial for Patients with Moderate to Severe Endometriosis-Associated Pain |
30 Apr 2021 |
9:05 pm |
GNW
|
|
|
ObsEva SA |
ObsEva SA presents posters at the ACOG Annual Clinical and Scientific Virtual Meeting April 30 - May 2, 2021 |
27 Apr 2021 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Initiates PRIMROSE 3 Bone Mineral Density Follow-Up Study in PRIMROSE 1 and PRIMROSE 2 Trial Participants |
22 Apr 2021 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Annual General Meeting 2021 |